Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion

Journal of Neuro-Oncology

Volumn 103, Issue 1, 2011, Pages 103-110

  Choi, Ki Young ^a   Jung, Tae Young ^a,b   Jung, Shin ^a,b   Kim, Young Hee ^b   Moon, Kyung Sub ^a,b   Kim, In Young ^a,b   Kang, Sam Suk ^a   Lee, Kyung Hwa ^a  

^a Chonnam National University   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

1p and 19q; MGMT; Oligodendroglial tumors; Prognosis; Radiologic findings

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CHILD; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE ENHANCEMENT; KARNOFSKY PERFORMANCE STATUS; MALE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE GENE; NEUROPATHOLOGY; NEURORADIOLOGY; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; SCHOOL CHILD; TUMOR CALCINOSIS; TUMOR LOCALIZATION; TUMOR NECROSIS;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NECROSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 79960017835     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0353-z     Document Type: Article

References (25)

1. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neurooncology. J Neuropathol Exp Neurol 62:111-126 (Pubitemid 36176946)
2. van den Bent M, Chinot OL, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neurooncology 5:128-138 (Pubitemid 36416842)
3. Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360-364 (Pubitemid 18098242)
4. Harris LC, Remack JS, Brent TP (1994) Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. Nucleic Acids Res 22:4614-4619 (Pubitemid 24354791)
5. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of lgiomas to alkylating agents. N Engl J Med 343:1350-1354
6. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:a1-a9 (Pubitemid 39069937)
7. Margain D, Peretti-Viton P, Perez-Castillo AM, Martini P, Salamon G (1991) Oligodendrogliomas. J Neuroradiol 18:153-160
8. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479 (Pubitemid 28482012)
9. Reifenberger G, Kros JM, Burger P, Louis DN, Collins VP (2000) Oligodendroglioma. In: Kleihues P, Cavenee WK (eds) World Health Organization classification of tumours, pathology and genetics of tumours of the nervous system. IARC Press, Lyon, France, pp 56-67
10. Jung TY, Jung S, Lee KH, Cao VT, Jin SG, Moon KS, Kim IY, Kang SS, Kim HS, Lee MC (2010) Nogo-A expression in oligodendroglial tumors. Neuropathology. doi:10.1111/j.1440-1789. 2010.01118.x
11. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369 (Pubitemid 351782844)
12. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866-875
13. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479 (Pubitemid 28482012)
14. Chinot O (2001) Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 4(Suppl 13):13-18 (Pubitemid 32879941)
15. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375-386 (Pubitemid 29370388)
16. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-4152 (Pubitemid 29363922)
17. Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK (2007) The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 18:639-652 (Pubitemid 47073545)
18. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322 (Pubitemid 38429028)
19. Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A (2008) Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88:293-298
20. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schuler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lutolf UM, Kleihues P, Ohgaki H (2004) Populationbased study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49-56 (Pubitemid 38961073)
21. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937 (Pubitemid 350276872)
22. Schiff D, Brown PD, Giannini C (2007) Outcome in adult lowgrade glioma: the impact of prognostic factors and treatment. Neurology 69:1366-1373 (Pubitemid 47482451)
23. Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, Ng HK (2001) Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 60:808-816 (Pubitemid 32678261)
24. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385 (Pubitemid 40038704)
25. El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy E, Muanza T, Melancon D, Kavan P, Guiot MC (2009) Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J Neurosurg 111(2):265-271